The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I trial of elotuzumab, lenalidomide, and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma.
S. Lonial
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; Merck; Millennium; Novartis; Onyx
Research Funding - Bristol-Myers Squibb; Celgene; Merck; Millennium; Novartis; Onyx
R. Vij
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene
Honoraria - Bristol-Myers Squibb; Celgene
T. Facon
Consultant or Advisory Role - Bristol-Myers Squibb
P. Moreau
No relevant relationships to disclose
X. Leleu
No relevant relationships to disclose
A. Mazumder
No relevant relationships to disclose
J. L. Kaufman
Consultant or Advisory Role - Keryx; Millennium; Onyx
Research Funding - Celgene; Merck
C. Westland
Employment or Leadership Position - Abbott Laboratories
Stock Ownership - Abbott Laboratories
C. Tsao
Employment or Leadership Position - Abbott Biotherapeutics
A. K. Singhal
Employment or Leadership Position - Abbott Laboratories
Stock Ownership - Abbott Laboratories
S. Jagannath
Consultant or Advisory Role - Celgene; Merck; Millennium